MediWound Ltd. to Post Q4 2022 Earnings of $0.53 Per Share, Oppenheimer Forecasts (NASDAQ:MDWD)

MediWound Ltd. (NASDAQ:MDWDGet Rating) – Research analysts at Oppenheimer raised their Q4 2022 earnings per share estimates for MediWound in a research report issued to clients and investors on Tuesday, January 17th. Oppenheimer analyst F. Brisebois now expects that the biopharmaceutical company will earn $0.53 per share for the quarter, up from their prior forecast of ($0.40). The consensus estimate for MediWound’s current full-year earnings is ($2.71) per share. Oppenheimer also issued estimates for MediWound’s Q1 2023 earnings at ($0.60) EPS, Q2 2023 earnings at ($0.54) EPS, Q3 2023 earnings at ($0.55) EPS, Q4 2023 earnings at ($0.56) EPS and FY2023 earnings at ($2.26) EPS.

MediWound (NASDAQ:MDWDGet Rating) last issued its earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.21). The firm had revenue of $5.80 million during the quarter, compared to the consensus estimate of $4.65 million.

Other equities analysts have also issued reports about the company. StockNews.com initiated coverage on MediWound in a research report on Friday, December 23rd. They set a “sell” rating on the stock. Maxim Group initiated coverage on MediWound in a research report on Thursday, December 22nd. They issued a “buy” rating for the company. HC Wainwright increased their price target on MediWound from $5.50 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, January 4th. Finally, Cowen increased their price target on MediWound from $6.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, December 30th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.40.

MediWound Stock Down 0.6 %

Shares of NASDAQ:MDWD opened at $13.58 on Friday. MediWound has a twelve month low of $8.05 and a twelve month high of $18.76. The stock’s 50 day moving average is $12.72 and its 200-day moving average is $12.03. The firm has a market capitalization of $79.05 million, a price-to-earnings ratio of -3.66 and a beta of 0.99.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC bought a new position in MediWound in the 3rd quarter valued at $405,000. Sargent Investment Group LLC grew its stake in MediWound by 7.2% in the 3rd quarter. Sargent Investment Group LLC now owns 562,350 shares of the biopharmaceutical company’s stock valued at $799,000 after purchasing an additional 37,600 shares during the period. Renaissance Technologies LLC grew its stake in MediWound by 3.8% in the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after purchasing an additional 17,600 shares during the period. Altium Capital Management LP bought a new position in MediWound in the 3rd quarter valued at $1,775,000. Finally, Armistice Capital LLC bought a new position in MediWound in the 3rd quarter valued at $2,663,000. Institutional investors own 13.58% of the company’s stock.

About MediWound

(Get Rating)

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Featured Stories

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.